Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million ...
Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results